IPSEN (OTCMKTS:IPSEY) Receives Consensus Recommendation of “Hold” from Analysts

IPSEN (OTCMKTS:IPSEY) has earned an average recommendation of “Hold” from the seven research firms that are covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company.

Several equities research analysts have recently weighed in on IPSEY shares. Jefferies Financial Group downgraded IPSEN from a “hold” rating to a “moderate sell” rating in a research report on Sunday, August 2nd. HC Wainwright reiterated a “buy” rating on shares of IPSEN in a report on Tuesday, June 30th. Barclays raised IPSEN from a “strong sell” rating to a “hold” rating in a research report on Thursday, September 17th. Finally, Zacks Research upgraded IPSEN to a “hold” rating in a report on Friday, May 29th.

IPSEN Trading Down 1.0%

Shares of OTCMKTS IPSEY opened at $41.97 on Monday. IPSEN has a 12-month low of $32.02 and a 12-month high of $51.10. The stock has a fifty day moving average price of $46.20 and a 200 day moving average price of $46.62.

About IPSEN

Ipsen SA is a France-based biopharmaceutical company that develops and commercializes specialty medicines for serious diseases. Its primary focus areas are oncology, rare diseases and neuroscience, with research and development activities aimed at addressing conditions that often have limited treatment options.

The company’s portfolio includes medicines such as Somatuline (lanreotide) for certain neuroendocrine tumors and endocrine disorders, Dysport (abobotulinumtoxinA) for selected neurological and muscular conditions, and oncology treatments including Cabometyx and Onivyde.